These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24260891)

  • 1. [Cyclic hydroxamic acids as chemosensitizers in cytostatic therapy].
    Konovalova NP; Vystoron IV; Sashenkova TE; Klimanova EN; Mishchenko DV; Allaiarova UIu; Goncharova SA; Raevskaia TA; Iakushchenko TN; Cherniak AV
    Vopr Onkol; 2013; 59(5):620-2. PubMed ID: 24260891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effectiveness of Cyclic Hydroxamic Acid CHA-5 against Drug-Resistant P388 Leukemia Strains.
    Goncharova SA; Vystorop IV; Raevskaya TA; Konovalova NP
    Bull Exp Biol Med; 2017 Jul; 163(3):385-388. PubMed ID: 28744633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of hydroxamic acids and sodium nitrate to enhance the antitumor effect of cyclophosphamide].
    Bogatyrenko TN; Kuropteva ZV; Sashenkova TE; Baĭder LM; Konovalova NP
    Vopr Onkol; 2013; 59(1):94-8. PubMed ID: 23814833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultralow doses of various drugs in chemotherapy of experimental tumors.
    Konovalova NP
    Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():45-7. PubMed ID: 12949646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
    Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
    Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
    Richon VM; Zhou X; Rifkind RA; Marks PA
    Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
    [No Abstract]   [Full Text] [Related]  

  • 7. Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells.
    Castro-Galache MD; Menéndez-Gutiérrez MP; Carrasco Garcia E; Garcia-Morales P; Martinez-Lacaci I; Saceda M; Ferragut JA
    Int J Biochem Cell Biol; 2007; 39(10):1877-85. PubMed ID: 17588800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy.
    Witt O; Lindemann R
    Cancer Lett; 2009 Aug; 280(2):123-4. PubMed ID: 19303208
    [No Abstract]   [Full Text] [Related]  

  • 9. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
    Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Spirocyclic Hydroxamic Acids as Effective Antiproliferative Agents.
    Neganova ME; Klochkov SG; Aleksandrova YR; Osipov VN; Avdeev DV; Pukhov SA; Gromyko AV; Aliev G
    Anticancer Agents Med Chem; 2021; 21(5):597-610. PubMed ID: 32459611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of histone deacetylase are potentially effective anticancer agents.
    Marks PA; Rifkind RA; Richon VM; Breslow R
    Clin Cancer Res; 2001 Apr; 7(4):759-60. PubMed ID: 11309319
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
    Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
    J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

  • 15. HDAC2 deficiency and histone acetylation.
    Ree AH; Folkvord S; Flatmark K
    Nat Genet; 2008 Jul; 40(7):812-3; author reply 813. PubMed ID: 18583969
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat.
    Grant S; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
    [No Abstract]   [Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
    Yoon CY; Park MJ; Lee JS; Lee SC; Oh JJ; Park H; Chung CW; Abdullajanov MM; Jeong SJ; Hong SK; Byun SS; Lee ES; Lee SE
    J Urol; 2011 Mar; 185(3):1102-11. PubMed ID: 21255805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
    Seo SY
    Arch Pharm Res; 2012 Feb; 35(2):197-200. PubMed ID: 22370774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.